Microcap Opportunities

Microcap Opportunities

Share this post

Microcap Opportunities
Microcap Opportunities
Delcath Has A Path To Profitability

Delcath Has A Path To Profitability

Sergio Heiber's avatar
Sergio Heiber
Jan 12, 2025
∙ Paid
5

Share this post

Microcap Opportunities
Microcap Opportunities
Delcath Has A Path To Profitability
Share

Delcath Systems (DCTH) is a hybrid medical device company that treats primary and metastatic liver cancer. It is very common for primary cancer from other body organs to metastasize in the liver as the liver filters out harmful substances in the blood.

The FDA cleared the company's Hepzato Kit in August 2023 for treating metastatic ocular melanoma ("mOM"…

Keep reading with a 7-day free trial

Subscribe to Microcap Opportunities to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 MicroCap Opportunities
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share